Global DNA Repair Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global DNA Repair Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
DNA damage leads to the incorporation of defects and aberrations in the genome that often result in functional mutations. When these mutations occur in genes coding for vital proteins and/or enzymes, it leads to the development of genetic diseases. However, our biological system is equipped with a robust repair mechanism capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body’s innate DNA repair mechanism and aid in the treatment of diseases associated with genetic aberrations.
DNA Repair Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global DNA Repair Drugs market is projected to reach US$ 1993.3 million in 2034, increasing from US$ 593.6 million in 2022, with the CAGR of 18.4% during the period of 2024 to 2034. Demand from Oncological and Stroke are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for DNA Repair Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, DNA Repair Drugs key manufacturers include 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group and GlaxoSmithKline, etc. 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb are top 3 players and held % sales share in total in 2022.
DNA Repair Drugs can be divided into PARP Inhibitors and Other, etc. PARP Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
DNA Repair Drugs is widely used in various fields, such as Oncological and Stroke, etc. Oncological provides greatest supports to the DNA Repair Drugs industry development. In 2022, global % sales of DNA Repair Drugs went into Oncological filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global DNA Repair Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
4SC AG
ARCAGY/ GINECO GROUP
Bristol Myers Squibb
British Columbia Cancer Agency
Cambridge University Hospitals NHS Foundation Trust
Genentech
Georgetown University
German Breast Group
GlaxoSmithKline
Jiangsu Hengrui Medicine
Johnson & Johnson
Jonsson Comprehensive Cancer Center
Karyopharm Therapeutics
KuDOS Pharmaceuticals
National Health Service
National Institutes of Health
Tesaro
Segment by Type
PARP Inhibitors
Other
Oncological
Stroke
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the DNA Repair Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of DNA Repair Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the DNA Repair Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of DNA Repair Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, DNA Repair Drugs introduction, etc. DNA Repair Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of DNA Repair Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
DNA Repair Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global DNA Repair Drugs market is projected to reach US$ 1993.3 million in 2034, increasing from US$ 593.6 million in 2022, with the CAGR of 18.4% during the period of 2024 to 2034. Demand from Oncological and Stroke are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for DNA Repair Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, DNA Repair Drugs key manufacturers include 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group and GlaxoSmithKline, etc. 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb are top 3 players and held % sales share in total in 2022.
DNA Repair Drugs can be divided into PARP Inhibitors and Other, etc. PARP Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
DNA Repair Drugs is widely used in various fields, such as Oncological and Stroke, etc. Oncological provides greatest supports to the DNA Repair Drugs industry development. In 2022, global % sales of DNA Repair Drugs went into Oncological filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global DNA Repair Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
4SC AG
ARCAGY/ GINECO GROUP
Bristol Myers Squibb
British Columbia Cancer Agency
Cambridge University Hospitals NHS Foundation Trust
Genentech
Georgetown University
German Breast Group
GlaxoSmithKline
Jiangsu Hengrui Medicine
Johnson & Johnson
Jonsson Comprehensive Cancer Center
Karyopharm Therapeutics
KuDOS Pharmaceuticals
National Health Service
National Institutes of Health
Tesaro
Segment by Type
PARP Inhibitors
Other
Segment by Application
Oncological
Stroke
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the DNA Repair Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of DNA Repair Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the DNA Repair Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of DNA Repair Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, DNA Repair Drugs introduction, etc. DNA Repair Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of DNA Repair Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices